How should an emergency department patient who is hypotensive and experiences syncope due to beta‑blocker‑induced bradycardia be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Beta-Blocker-Induced Bradycardia with Hypotension and Syncope in the Emergency Department

For a hypotensive patient with syncope due to beta-blocker-induced bradycardia, immediately administer atropine 0.5-1 mg IV as first-line therapy, followed by glucagon 3-10 mg IV bolus if unresponsive, and prepare for transcutaneous pacing while initiating high-dose insulin therapy (1 unit/kg bolus, then 0.5-1 unit/kg/hr infusion with dextrose) for refractory cases. 1, 2, 3

Initial Stabilization and Assessment

When a patient presents with hypotension and syncope in the context of beta-blocker use, your immediate priorities are:

  • Secure IV access and place on continuous cardiac monitoring
  • Check vital signs focusing on heart rate, blood pressure, and rhythm
  • Obtain ECG immediately to assess for bradycardia, AV blocks, or QRS widening (predictor of severe ventricular arrhythmia)
  • Draw labs: potassium (hyperkalemia potentiates beta-blocker toxicity), renal function (accumulation of renally-cleared beta-blockers like atenolol), glucose, and lactate 2, 4, 5

Critical pitfall: The combination of renal failure, hyperkalemia, and beta-blockers creates a synergistic bradycardia (BRASH syndrome) that is particularly refractory to standard treatments 4, 5. Always check potassium and creatinine immediately.

Pharmacologic Management Algorithm

First-Line: Atropine

Administer atropine 0.5-1 mg IV (may repeat every 3-5 minutes up to maximum 3 mg total) 6, 2. Atropine remains the first-line drug for acute symptomatic bradycardia with hemodynamic compromise.

Important caveat: Atropine may be ineffective in beta-blocker toxicity because the bradycardia is not mediated by parasympathetic activity but by direct beta-receptor blockade 1. If no response after 1-2 doses, move immediately to next steps rather than continuing to maximum atropine dose.

Second-Line: Glucagon

If bradycardia persists after atropine, give glucagon 3-10 mg IV bolus over 3-5 minutes, followed by continuous infusion of 3-5 mg/hr 1, 2, 3, 7. Glucagon counteracts beta-blocker effects by activating hepatic adenyl cyclase independent of beta-receptors, providing positive inotropic and chronotropic effects.

Side effects to anticipate: Nausea and vomiting are common—protect the airway if mental status is altered 2, 3.

Third-Line: High-Dose Insulin Therapy

For refractory hypotension/bradycardia, initiate high-dose insulin: 1 unit/kg IV bolus, followed by 0.5-1 unit/kg/hr continuous infusion 1, 2, 3, 7. This is the most effective therapy for severe beta-blocker toxicity with cardiogenic shock.

Mandatory co-administration:

  • Dextrose infusion to maintain euglycemia (monitor glucose every 15-30 minutes initially)
  • Potassium supplementation as needed (insulin drives potassium intracellularly) 2

High-dose insulin improves myocardial contractility and has shown better outcomes with fewer vasoconstrictive complications compared to vasopressor-only therapy 1.

Adjunctive Vasopressor Support

If hypotension persists despite above measures, add vasopressor support 1, 2:

  • Dopamine 5-20 mcg/kg/min IV (start at 5 mcg/kg/min, increase by 5 mcg/kg/min every 2 minutes) 2
  • Epinephrine 2-10 mcg/min IV (alternative or addition to dopamine) 2
  • Isoproterenol 1-20 mcg/min IV (pure beta-agonist, but use cautiously—may worsen ischemia) 2

Caution: Doses of dopamine >20 mcg/kg/min may cause vasoconstriction and arrhythmias 2.

Calcium Administration

Consider calcium chloride 1-2 g IV or calcium gluconate 3-6 g IV 2, 3, 7. While calcium is more established for calcium channel blocker toxicity, it may provide modest benefit in beta-blocker overdose, particularly if hyperkalemia is present 1, 7.

Transcutaneous/Transvenous Pacing

Initiate transcutaneous pacing if bradycardia remains unresponsive to atropine and pharmacologic therapy 6, 2. This is a Class IIa recommendation for unstable patients who don't respond to atropine.

  • Transcutaneous pacing is preferred initially (non-invasive, rapid deployment)
  • Prepare for transvenous pacing if transcutaneous pacing fails or prolonged pacing is anticipated 8, 6

Reality check: Pacing may be ineffective in severe beta-blocker toxicity due to profound myocardial depression—don't delay pharmacologic therapy while attempting pacing 1.

Extracorporeal Support

For refractory cardiogenic shock despite maximal pharmacologic therapy and pacing, consider VA-ECMO 1, 7. This is a Class 2a recommendation based on case series showing life-saving potential in patients with persistent pump failure.

Contact your institution's ECMO team early if the patient is deteriorating despite aggressive medical management.

Hemodialysis Consideration

For atenolol or sotalol overdose specifically, hemodialysis may be reasonable 1. These are hydrophilic, renally-cleared beta-blockers that can be removed by dialysis. This is less effective for lipophilic agents like propranolol or metoprolol.

What NOT to Do

Do NOT use intravenous lipid emulsion (ILE) therapy—it is Class 3: No Benefit for beta-blocker poisoning 1. Unlike local anesthetic toxicity, ILE has not shown benefit in beta-blocker overdose.

Disposition and Monitoring

  • Admit to ICU for continuous cardiac monitoring, frequent vital signs, and serial glucose/potassium checks
  • Continue high-dose insulin infusion for 24-48 hours in severe cases
  • Monitor for delayed toxicity with extended-release formulations
  • Withhold beta-blocker and reassess need/dose before discharge

Key Clinical Pearls

  1. BRASH syndrome (Bradycardia, Renal failure, AV nodal blockers, Shock, Hyperkalemia) represents a synergistic toxicity that is particularly difficult to treat—address all components simultaneously 4, 5

  2. Atropine often fails in beta-blocker toxicity—don't waste time with repeated doses if initial response is poor 1

  3. High-dose insulin is your most effective therapy for severe toxicity—start early rather than waiting for complete failure of other measures 1, 2

  4. Glucagon works quickly but effects are transient—must use continuous infusion, not just bolus 2, 3

  5. The evidence base for beta-blocker toxicity management comes primarily from case reports and small series rather than randomized trials, but the 2023 AHA Focused Update provides the most current expert consensus 1

References

Related Questions

What is the most important initial step in managing a patient with symptomatic bradycardia (abnormally slow heart rate) and hypotension (low blood pressure)?
What is the approach to managing bradycardia in an asymptomatic underweight patient?
How to manage asymptomatic bradycardia (abnormally slow heart rate) on the 3rd postoperative day?
How should a 71‑year‑old patient with a heart rate of 42 beats per minute be evaluated and managed?
What is the appropriate management of bradycardia in a patient with prostate cancer and a history of gastrointestinal bleeding, considering the use of atropine (anticholinergic) and epinephrine (adrenergic agonist)?
What is the recommended management for a 39‑week pregnant patient with a transverse lie and maternal severe bradycardia?
What should be done for a patient with atrial fibrillation who develops a slow ventricular response after beta‑blocker therapy?
Can elevated serum creatinine along with increased blood urea nitrogen or uric acid differentiate obstructive (post‑renal) from prerenal acute kidney injury?
What is the incidence of methotrexate‑induced acute interstitial pneumonitis?
What are the indications, surgical technique, and peri‑operative management for total knee arthroplasty in a patient with a symptomatic varus knee deformity that has failed conservative treatment?
Should a patient with a symptomatic varus knee due to advanced medial compartment osteoarthritis undergo total knee replacement?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question